6:14 PM
Apr 26, 2016
 |  BC Extra  |  Company News

NICE backs Novartis' Entresto

The U.K.'s NICE issued draft guidance recommending heart failure drug Entresto sacubitril/valsartan from Novartis AG (NYSE:NVS; SIX:NOVN). The drug is recommended for patients with moderate...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >